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Tuberculosis is unique among the major infectious diseases in that it lacks accurate rapid point-of-care
diagnostic tests. Failure to control the spread of tuberculosis is largely due to our inability to detect and treat all
infectious cases of pulmonary tuberculosis in a timely fashion, allowing continuedMycobacterium tuberculosis
transmission within communities. Currently recommended gold-standard diagnostic tests for tuberculosis are
laboratory based, and multiple investigations may be necessary over a period of weeks or months before
a diagnosis is made. Several new diagnostic tests have recently become available for detecting active
tuberculosis disease, screening for latent M. tuberculosis infection, and identifying drug-resistant strains of
M. tuberculosis. However, progress toward a robust point-of-care test has been limited, and novel biomarker
discovery remains challenging. In the absence of effective prevention strategies, high rates of early case
detection and subsequent cure are required for global tuberculosis control. Early case detection is dependent on
test accuracy, accessibility, cost, and complexity, but also depends on the political will and funder investment to
deliver optimal, sustainable care to those worst affected by the tuberculosis and human immunodeficiency virus
epidemics. This review highlights unanswered questions, challenges, recent advances, unresolved operational
and technical issues, needs, and opportunities related to tuberculosis diagnostics.
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Tuberculosis remains one of the most important causes of death
from an infectious disease [1, 2], with the latest World Health
Organization (WHO) figures [2] indicating that in 2010 there
were 8.8 million incident cases of tuberculosis, with about 13%
of tuberculosis cases occurring among people living with human
immunodeficiency virus (HIV). There were 1.1 million deaths
from tuberculosis among HIV-negative people and an addi-
tional 350 000 deaths from HIV-associated tuberculosis. There
were 3.2 million incident cases of tuberculosis and 320 000
deaths from tuberculosis among women in 2010. In 2009, there
were almost 10 million children who were orphaned as a result
of parental deaths caused by tuberculosis. In addition, the global
emergence of multidrug-resistant tuberculosis, extensively drug-
resistant tuberculosis, and more recently, totally drug-resistant
tuberculosis presents a formidable challenge to tuberculosis
control, especially in Eastern Europe, Asia, and sub–Saharan
Africa [3, 4].
Mycobacterium tuberculosis is transmitted via minute aerosol
droplets that remain suspended in the air for prolonged periods
of time, posing a particular infection-control challenge. Differ-
ent outcomes may result following inhalation of an infectious
droplet containing M. tuberculosis [5]. The probability of de-
velopment of active clinical tuberculosis after being infected
with M. tuberculosis is very small. Less than 10% of those
infected develop symptoms and signs of active disease over
a lifetime; the actual figure depends on geographical location,
M. tuberculosis strain type, genetic background, immunosup-
pression, and other risk factors. The majority of immunocom-
petent individuals either eliminate M. tuberculosis or contain it
in a latent state in which an equilibrium is established between
host and pathogen. Latent M. tuberculosis infection is a clinical
condition that occurs after an individual is infected with
M. tuberculosis, the infection is established, and the elicited
host immune response contains the M. tuberculosis bacilli in
a quiescent state, thereby preventing active replication and tissue
damage. M. tuberculosis bacilli are present in host tissue, yet
there are no clinical symptoms or signs of active tuberculosis
disease. Importantly, reactivation of latent M. tuberculosis
bacilli can occur at any time in the infected individual’s
lifetime, depending on the waning of immunity due to
chronic diseases such as diabetes, alcoholic liver disease, HIV
coinfection, and use of steroids or other immunosuppre-
ssive drugs. Thus, when active disease occurs in later life,
it becomes difficult to ascertain whether it is due to re-
activation of latent M. tuberculosis bacilli or to a new infect-
ion with another M. tuberculosis strain. Due to the ubiquitous
nature of M. tuberculosis, WHO estimates that approximately
2 billion people (one-third of the world’s population) have
been infected with M. tuberculosis [6]. Accurate classification of
M. tuberculosis infection and tuberculosis disease status is essen-
tial given that treatment approaches latent M. tuberculosis in-
fection and active tuberculosis disease are entirely different.
Currently recommended so called gold-standard diagnostic
tests for tuberculosis are laboratory based, and multiple inves-
tigations may be necessary over a period of weeks or months
before a diagnosis is made [7]. In resource-limited settings,
light microscopic examination of Ziehl-Neelsen–stained sputum
specimens is often the only tuberculosis test available. It is used
mainly for suspected pulmonary tuberculosis cases and is an
insensitive technique that performs poorly in young children [8]
and individuals who are immunocompromised [7, 9]. It also
fails to detect extra pulmonary disease (for which invasive
sampling to obtain lymph node aspirate, cerebral spinal fluid, or
other specimens may be required) or identify drug resistance
[7, 9].
THE NEED FOR MORE ACCURATE AND RAPID
DIAGNOSTICS
Despite improvements in tuberculosis control program per-
formance, active tuberculosis case detection rates in many re-
gions remain at unacceptable levels. For example, only 60%
of the estimated total tuberculosis caseload is detected in the
WHO Africa Region, thus close to half of active tuberculosis
cases remain undetected and continue to transmit M. tubercu-
losis [2]. Figure 1 illustrates that in some tuberculosis- and
tuberculosis/HIV-endemic countries, less than 4 of 10 cases are
detected, with the bulk of HIV-associated tuberculosis cases
remaining undiagnosed. Optimal detection of active tubercu-
losis or latent M. tuberculosis infection in HIV-infected in-
dividuals remains a major challenge in resource-limited settings.
Furthermore, only 7% of the estimated 500 000 new multidrug-
resistant tuberculosis patients each year are detected, most of
them following prolonged diagnostic delay [3]. Failure to detect
drug resistance results in inappropriate treatment and pre-
mature death of the individual patient, but it also facilitates
amplification of resistance and ongoing transmission within
the community, greatly worsening the situation [4, 8].
Although HIV diagnosis has been greatly assisted by the de-
velopment of robust point-of-care (POC) diagnostics suitable
for field use, the diagnosis of tuberculosis remains clinically
challenging and logistically difficult in resource-limited set-
tings [11]. A major difference between the 2 diseases is the
need to differentiate latent M. tuberculosis infection from
active tuberculosis disease in tuberculosis suspects, which
greatly complicates standard diagnostic approaches. Another
difference is their ability to attract commercial investment
for product development, as the market for HIV tests is
perceived to be considerably more lucrative than that for
tuberculosis [12].
In industrialized countries, radiography, other advanced
imaging techniques, rapid culture methods, and nucleic acid
amplification tests (NAATs) are used to supplement light
and light-emitting diode (LED) microscopy for the diagnosis
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of active tuberculosis disease [1]. Sensitivity is also enhanced
by using tests in combination, induced sputum, or invasive
techniques such as bronchoscopy with lavage and tissue bi-
opsies. Unfortunately, many of these technologies are beyond
the reach of many of the world’s tuberculosis cases. In Africa
and Southeast Asia, the WHO regions most heavily affected
by tuberculosis, per capita government expenditure on health
during 2007 was just $34 and $15, respectively [13]. Although
tuberculosis treatment is free, patients are sometimes required
to pay for some of the diagnostic tests in the public sector
[14, 15], and some patients opt to consult private practi-
tioners at their own cost, which results in multiple visits to
confirm a diagnosis, resulting in further expenditures for
poorer patients [16, 17]. The limitations of the existing tu-
berculosis diagnostics toolbox contribute to diagnostic delays
with serious consequences for public health efforts to control
the epidemic [7, 18]. The vast majority of tuberculosis sus-
pects in endemic countries present to peripheral healthcare
facilities that may have no electricity, no running water, and
limited or no laboratory facilities. Childhood tuberculosis [9],
drug-resistant tuberculosis, and sputum smear–negative pul-
monary and extrapulmonary tuberculosis in adults remain
the greatest diagnostic challenges [1, 9]. It is estimated that
availability of a widely used rapid diagnostic test for tuberculosis
that was 100% accurate and that led to initiation of treatment
could avert 625 000 tuberculosis deaths each year [18].
IDEAL DIAGNOSTIC TEST CHARACTERISTICS
The ideal tuberculosis test would be a POC device capable
of providing an on-the-spot accurate diagnosis of active
tuberculosis in HIV-infected and -uninfected adults and
children with pulmonary and extrapulmonary tuberculosis;
it should also be able to detect resistance to the first-line
tuberculosis drugs to avoid initial treatment failure [11] and
to allow for rapid prescription of appropriate and specific
therapy that prevents the use of inappropriate drugs, thereby
inducing drug resistance. The ability of the test to distinguish
between active tuberculosis disease and latent M. tuberculosis
infection is critical. WHO adopted a policy to screen all
HIV-infected persons for active tuberculosis as well as latent
M. tuberculosis infection because tuberculosis remains the
leading cause of death among HIV-infected patients and
those with latent M. tuberculosis infection are at high risk of
progression to active tuberculosis in the absence of preventive
therapy [19]. The overall impact of any new diagnostic tests
for active tuberculosis disease or latent M. tuberculosis infec-
tion will depend on the extent of their uptake into national
tuberculosis programs, affordability both from the patient
and health system perspective, the quality and durability of
the diagnostic devices, and access to appropriate treatment
following diagnosis [20–22]. The need to increase research
and development into POC tests for tuberculosis has received
Figure 1. Estimated global tuberculosis case detection rates. Compiled from data presented in the Global Tuberculosis Control Report (WHO. Global
tuberculosis control. Geneva: World Health Organization; 2010.).
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increasing attention in recent years, but there is still a lack
of a focused and strategic approach and insufficient integra-
tion between areas of biological discovery and test develop-
ment and the establishment of well-characterized specimen
repositories for initial test evaluation [23, 24].
IDENTIFYING ACCURATE AND NOVEL
BIOMARKERS
A biomarker can be defined as a characteristic that is objectively
measured and assessed as an indicator of normal biological
processes, pathogenic processes, or pharmacological responses to
a therapeutic intervention [1, 24–27]. Biomarkers can be either
host- or pathogen-specific and may advance knowledge by
providing information about the pathogenic process, including
the current health status and future disease risk of the patient.
Thus, there is a need for a specific biomarker to classify patients
at a single time point as having active tuberculosis, latent
M. tuberculosis infection, or no disease [24, 25]. Although these
classifications are important from a pragmatic clinical stand-
point, there is increasing acknowledgment within the field
that these are unlikely to exist as simple compartmentalized
states but rather reflect a spectrum [26] that may be pro-
foundly impacted by cofactors that alter the host–pathogen
relationship [5]. Other potential applications for biomarkers
include predicting future reactivation risk and monitoring
the eradication of latent M. tuberculosis infection. They may
also provide pragmatic endpoints for clinical trials by serving
as surrogate markers of cure following tuberculosis treat-
ment or protective efficacy following tuberculosis vaccina-
tion. The challenge remains to ensure that any advances made
in biomarker discovery translate into diagnostics suitable for
implementation in settings that carry the bulk of the global tu-
berculosis disease burdendin particular, a detection platform
that can be implemented as an affordable POC test. Progress
in developing these specific tuberculosis biomarkers has been
slow [1, 24–28], although several studies are underway using
newer technology with multiplexed assays to compare a variety
of gene expression profiles among patients with tuberculosis,
healthy people with latent M. tuberculosis infection, and healthy
people with no exposure to M. tuberculosis. These studies are
measuring several variables with proteomics, transcriptomics,
and metabolomics and have been reviewed elsewhere [25, 26].
Defining the correlates of immune protection in individuals with
latent M. tuberculosis infection presents a major challenge in
tuberculosis- and tuberculosis/HIV-endemic areas.
CREATING WELL-CHARACTERIZED SPECIMEN
REPOSITORIES FOR NEW TUBERCULOSIS
DIAGNOSTICS
Central repositories with well-characterized specimens are
critical to identify and validate new diagnostic tests [29, 30]. An
independent source of these validation samples is important
for several reasons. First, most small companies and academic
units will not have sufficient funds to establish a full sample
bank, and the lack of a set of validation samples should not
be a major barrier to diagnostic test development. Second, the
independence of the sample bank will make the validation
process more rigorous for the tuberculosis research com-
munity. Several banks are currently in existence, but accessibility
is highly variable, sample collection processes are not stan-
dardized, disease phenotypes are often poorly characterized,
and the sample types and volumes are not all clearly defined.
This means that developers may arrive at different validation
results depending on the sample set used [6]. In addition,
samples are rarely collected and stored in a manner suitable for
research on metabolic markers or volatile compounds. Ad-
dressing such shortfalls will require greater investment that is
likely to be beyond the financial and logistical limits of small
biotech companies and academic research units. The well-
established WHO/Special Programme for Research and Training
in Tropical Diseases (TDR) specimen bank, although deficient
in important areas, offers the basis of a model that could better
meet the needs of the POC tuberculosis test development
community [31]. Importantly, it provides an open access re-
source for developers. However, without substantial invest-
ments in strengthening and improving this resource, it will
fail to address the needs of the tuberculosis research community.
Finally, there is a need to create a pediatric resource, which
would be challenging and expensive, but lack of such a resource
is a crucial deficiency in current efforts.
IMPROVING SAMPLE COLLECTION AND
PROCESSING
The success of any new diagnostic test will depend on the ability
to obtain good quality material from the site of disease, which
is often not trivial in the environments where POC diagnostics
are most needed. Although sputum remains one of the key
specimens for tuberculosis diagnosis, the collection of good
quality samples adequate for proper diagnosis is difficult,
and current sputum processing methods are crude [32]. This
represents a particularly important limitation in settings with
a high burden of HIV/M. tuberculosis coinfection and pedi-
atric tuberculosis because these patients are often unable to
produce a quality specimen suitable for analysis [32]. Even
if adequate sputum samples are collected, current bacterial
decontamination methods probably reduce viable M. tuber-
culosis counts by at least 1 log, whereas mycobacterial con-
centration in the test sample is suboptimal. Identification
of samples other than sputum, such as blood, urine, lung or
gastric lavage fluid, biopsies, aspirates or effusions, is critical
for improving access to diagnosis for these patient populations.
A number of alternative approaches to obtain respiratory
S150 d JID 2012:205 (Suppl 2) d McNerney et al
samples exist (ie, nebulizer systems, string test, nasopha-
ryngeal aspiration, lung flute), but these have practical lim-
itations and as a consequence have not been widely adopted
in programmatic settings.
RECENT ADVANCES IN TUBERCULOSIS
DIAGNOSTICS
Over the past 5 years, several new tests have become available
for detecting active tuberculosis disease, screening for latent
M. tuberculosis infection, and identifying drug-resistant strains
of M. tuberculosis [1, 25, 27]. The contribution made toward
improving case detection and cure rates as well as global control
of drug-susceptible and drug-resistant tuberculosis will vary
depending on the accuracy, cost, and complexity of the test and
on the political will and funder investment available to ensure
delivery. Technologies that are not affordable outside of well-
funded aid programs or that can only function under referral
laboratory conditions are unlikely to reach the mass of un-
diagnosed tuberculosis in the high-burden countries of Africa
and Asia. One approach has been to improve the technologies
we already have, making them easier to use. LED microscopes
that can be used with fluorescent stains are replacing light
microscopy [33]. New approaches are being tested in which
patients provide multiple specimens for examination during
1 visit to the clinic, rather than being asked to return at a later
date [34]. Front-loading, or so-called 1-day diagnosis, has been
endorsed by WHO under defined programmatic conditions.
SEROLOGICAL TESTS
A number of commercial antibody-based tuberculosis diag-
nostic tests have been developed and are on sale, although
clinical validation is usually absent and current test performance
is poor [35]. In a comparative study of 19 different tests, the
highest sensitivity observed was 59.7%, with some tests de-
tecting less than 1 in 10 tuberculosis patients [35]. A recent
meta-analysis commissioned by WHO on currently available
commercial serological tests showed very low data quality,
inconsistent and imprecise estimates of sensitivity and speci-
ficity, and no evidence that existing commercial serological
assays improve patient-important outcomes [36]. How-
ever, the market for these tests is huge, and they are mainly
sold to private practitioners in developing countries where
regulatory control of diagnostic tools is lacking.
INTERFERON GAMMA RELEASE ASSAYS
Secretion of interferon gamma by T cells following stimulation
with specific M. tuberculosis antigens indicates past or current
infection with or current disease due to M. tuberculosis. Two
commercial interferon gamma release assays (IGRAs), the
QuantiFERON-TB Gold In-Tube assay (QFT-GIT, Cellestis
Ltd, Australia) and the T-SPOT.TB (Oxford Immunotec, UK),
which measure interferon gamma released following incuba-
tion of patient blood with antigens specific to M. tuberculosis,
namely early secretory antigenic target-6 (ESAT-6), culture
filtrate protein 10 (CFP-10), and the tuberculosis 7.7 antigens,
have been developed [1, 25, 36–38]. Despite initial hype fol-
lowing discovery, the ensuing prolific scientific interest, and
numerous studies conducted in a variety of clinical situations
in adults and children across the world, the 2 IGRAs do not
differentiate latent M. tuberculosis infection from active tu-
berculosis disease and are not significantly superior to tuber-
culin skin tests (TSTs), including in their ability to identify
HIV-infected individuals with latent M. tuberculosis infection
[39]. Recent reviews and meta-analysis concluded that neither
IGRAs nor the TST have high accuracy for the prediction of
active tuberculosis, although use of IGRAs in certain pop-
ulations might reduce the number of people being considered
for preventive treatment. Thus IGRAs cannot and should not
be used in isolation to inform treatment decisions for sus-
pected cases of tuberculosis [40, 41]. UK National Institute
for Health and Clinical Excellence guidelines [42] suggest
a supportive role for IGRAs alongside traditional TSTs and
other routine tuberculosis screening tests in the diagnostic
workup of patients suspected of having active tuberculosis.
IGRAs are not recommended as tests used to predict active
tuberculosis and conduct surveillance of healthcare staff or
outbreak investigations, and for contact screening, including
screening of children and HIV-infected individuals [40, 41].
WHO advises against the use of IGRAs over TSTs in low- and
middle-income countries with typically high tuberculosis and/or
HIV burdens [40, 41] as a diagnostic test. An expert scientific
panel recently convened by the European Centers for Disease
Prevention and Control to clarify these issues and review the
scientific evidence base for use of IGRAs in clinical practice
concluded that IGRAs should not and cannot replace the ex-
isting standard diagnostic methods for the diagnosis of active
tuberculosis [40]. The panel also emphasized that a negative
IGRA result does not exclude active tuberculosis disease and in
high-risk groups, a negative IGRA does not rule out M. tu-
berculosis infection. The expert panel suggested that in order to
identify individuals with latent M. tuberculosis infection for
whom preventive treatment could be considered, IGRAs may be
used only in conjunction with an overall risk assessment to pro-
vide supplementary information as part of a diagnostic workup.
IGRAs are an improvement over TSTs in that they are less
prone to false positives caused by nontuberculosis mycobacteria
or bacille Calmette-Gue´rin have an internal control, and do
not require a follow-up visit to assess the reaction. However,
IGRAs are often wrongly marketed as tuberculosis diagnostic
tests despite their limited clinical utility. They are also expensive
and require fastidious sample handling to ensure accuracy. It
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has taken over a decade of enormous amounts of effort and
time and investment of a large amount of funding and resources
into IGRA evaluation studies across the globe to reach these
recommendations, which will not have a major impact on
achieving tuberculosis control. The results also do not reflect
the initial excitement, hype, and expectations after IGRAs were
launched as a major breakthrough in tuberculosis diagnostics.
This also exposes the desperate state of appropriate evaluation
of tuberculosis diagnostics in well-designed research studies
conducted with the required scientific rigor. It is vital, therefore,
that evaluation of any new diagnostic tests does not suffer from
a protracted and costly, yet scientifically invalid, evaluation
process. There is a dire need to have comprehensive networks
of funders, multidisciplinary researchers, and good clinical/
good laboratory practice–capable field sites in several geo-
graphical locations that could undertake such evaluations
using standardized protocols. Industry involvement in diag-
nostic test evaluation is another primary concern and a po-
tential confounder of results and reason for publication bias.
FLOW CYTOMETRY ASSAYS OF THE
M. tuberculosis–SPECIFIC T-CELL RESPONSES
Polychromatic flow cytometry has been used to define the
functional profile of M. tuberculosis–specific T-cell responses
in cohorts of patients with active disease and latent M. tuber-
culosis infection [43]. The panel used included a viability
marker, CD3, CD4, and CD8 to determine T-cell lineage,
and interleukin 2, tumor necrosis factor alpha (TNF-a), and
interferon gamma antibodies to comprehensively assess the
cytokine functional profile. The proportion of single TNF-a
M. tuberculosis–specific CD4 T cells were found to be the
strongest predictor measure of discrimination between active
disease and latent M. tuberculosis infection. The sensitivity of
the CD4 T-cell signature was 100% and the specificity was
96% for the data generated from a European cohort [43]. Other
flow-cytometric-based assays may include major histocom-
patibility complex (MHC) class I and MHC class II tetramer
complexes that allow direct visualization, without ex vivo
manipulation, of CD81 and CD41 T-cell responses directed
against defined MHC–M. tuberculosis peptide complexes [44–46].
T-cell responses can now be visualized without the need to
show T-cell function.
NUCLEIC ACID AMPLIFICATION TESTS
The most significant advance toward a POC test for tuberculosis
has come in the field of nucleic acid amplification with the
launch of the GeneXpert MTB/RIF assay (Cepheid, Sunnyvale,
CA) [47, 48]. The GeneXpert multifunctional diagnostic plat-
form is an automated closed system that performs real-time
polymerase chain reaction (PCR), producing results in less than
2 hours. The assay is capable of detecting the M. tuberculosis
complex while simultaneously detecting rifampicin (RIF) re-
sistance (targeting the RIF resistance–determining region of
the rpoB gene and associated M. tuberculosis–specific flanking
regions). Disposable cassettes are used, and following a manual
sample liquefaction step, the test is fully automated. The test
is easy to use and does not require specialist training other
than very basic use of a computer. Assay sensitivity is higher
than that of smear microscopy and close to that of culture
[47–54]. When testing a single sputum sample, the assay detects
98%–100% of sputum smear–positive disease and 57%–83%
of smear-negative disease among prospectively studied tuber-
culosis suspects [52]. In addition, the assay has utility in diag-
nosing extrapulmonary tuberculosis from a range of samples
from extrapulmonary sites, with sensitivities of 53%–95% [55].
The assay is also highly specific with no cross-reaction with
nontuberculous mycobacteria or normal flora of the respiratory
tract [50]. Among children with culture-confirmed pulmonary
tuberculosis, the assay rapidly detected all smear-positive cases
and 61% of smear-negative cases when testing 2 induced
sputum samples [56]. The assay has also been assessed for
screening patients prior to antiretroviral therapy in South
Africa. Case detection increased by 45%dfrom 28% using
smear microscopy to 73% using Xpert MTB/RIF assay [57].
Routine screening of all patients prior to antiretroviral ther-
apy is likely to be a highly cost-effective strategy in this very
high-burden setting.
Despite the findings of very high sensitivity and specificity
for detection of RIF resistance in the initial multicountry eval-
uation [47], several studies have since detected numbers of
false-positive cases of RIF resistance when compared with other
testing methods and to rpoB gene sequencing [53, 57] in set-
tings with low RIF resistance prevalence. The current WHO
implementation guide recommends use of a second testing
method to confirm RIF resistance in these settings and to test for
resistance to second-line drugs whenever multidrug resistance
is detected [58].
Thus, while the Xpert MTB/RIF assay represents a very sen-
sitive diagnostic test for RIF resistance in high-risk populations
groups as well as a very sensitive screening test for RIF resistance
in low-risk populations, it cannot universally be applied as
a definitive test for point of care [59–62].
The Xpert MTB/RIF assay was shown not to be associated
with generation of infectious bioaerosols and resulted in a lower
biohazard risk compared with that of conventional smear mi-
croscopy [49]. This suggests that the assay might reasonably
be done without the need for special biosafety equipment,
which is lacking in most resource-limited settings. A subse-
quent multicountry implementation study found that the
assay could be successfully implemented at the district and
subdistrict level in urban settings, greatly accelerating di-
agnosis and start of tuberculosis treatment and reducing the
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proportion of untreated disease [52]. The Xpert MTB/RIF
assay was rapidly endorsed by WHO in December 2010 for
use in tuberculosis-, multidrug-resistant tuberculosis-, and
tuberculosis/HIV-endemic regions using a risk-based approach
to testing [58].
The new test has generated much excitement in tuberculosis
diagnostic circles, although some operational concerns remain.
[59–62]. Although this is a long-awaited breakthrough for
tuberculosis diagnostics, the rate-limiting steps of this new
technology are that this device may not be useful where in-
frastructure limits operation and maintenance of the real-time
PCR platforms and associated personal computer. Furthermore,
required annual instrument maintenance may be another hin-
drance. Various corrective measures have been introduced, in-
cluding revisions to the diagnostic platform software and
redesign of one of the cartridge oligonucleotide probes. As part
of the routine product improvement cycle, minor changes were
made to the Xpert MTB/RIF assay during the course of the last
12 months. The new software and cartridge combination, called
G4 version cartridge, has just been released [63]. Although the
Xpert MTB/RIF assay is a major advance of a new generation
of easy-to-use nucleic acid amplification tests, other amplifica-
tion technologies are required that do not require thermocycling
and have potential to improve on the Xpert MTB/RIF assay,
including detecting resistance to drugs other than RIF.
DIAGNOSTIC TESTS FOR ACTIVE
TUBERCULOSIS IN CHILDREN
In endemic areas, an estimated 15%–20% of tuberculosis cases
are children [2]. Although older children (.10 years of age)
often develop adult-type disease and should access sputum-
based diagnostic services, young children who are unable to
expectorate carry the greatest disease burden [8]. In addition,
young children rarely develop the lung cavities typical of adult
tuberculosis, resulting in reduced organism loads compared
with adult patients. Collecting respiratory specimens from
young children is challenging. Gastric aspirates and induced
sputum are frequently used in combination to optimize the
yield [9, 64, 65] but may require hospitalization. Creative
strategies for collecting effective respiratory specimens linked to
maximal extraction techniques and sensitive analysis tools are
urgently needed. Refining the string test may assist specimen
collection [66], whereas microparticle filters and magnetic beads
may offer improved organism concentration [67] compared
with standard centrifugation but have not been tested in pedi-
atric specimens.
Initial studies using the Xpert MTB/RIF assay excluded chil-
dren [19], but subsequent studies have shown substantial utility
for rapid diagnosis of culture-confirmed cases [56]. Most of
the clinically suspected pediatric tuberculosis cases are not con-
firmed by culture [53], and identifying the optimal reference
standard against which novel diagnostic tests should bemeasured
poses a major dilemma. Clear, well-defined case definitions with
high sensitivity and specificity are required for conducting eval-
uation studies of new diagnostics in children [68]. Where
the presence of M. tuberculosis is not confirmed, the value of
a positive new test when the conventional gold-standard test
is positive will require further study. Autopsy and biopsy
studies may provide invaluable insight into evaluation of
new diagnostic tests under these circumstances and resolve
the difficulty of distinguishing between a false positive or
true positive interpretation for determining specificity and
sensitivity [69]. The Xpert MTB/RIF assay has been shown
to be applicable to nonsputum samples from patients with
extrapulmonary tuberculosis [70] and thus may yield improved
diagnostic rates in children. Nonrespiratory specimens such as
cerebrospinal fluid are also paucibacillary, and diagnostic yield
may be improved with adequate preconcentration of these sam-
ples [70]. Some advances have been made, such as recognition
that fine-needle aspiration biopsy offers a minimally invasive
technique with excellent mycobacterial yield and the ability
to rule out important alternative diagnoses in children with
a peripheral lymph node mass [71, 72]. This can be done in a
decentralized fashion using rechargeable battery–operated
LED fluorescent microscopy [73]. For children with uncertain
disseminated (miliary) tuberculosis, bone marrow biopsy may
assist histological or microbiological confirmation [74]. If
adequate specimens are collected, both commercial and non-
commercial liquid culture techniques, such as microscopic
observation for drug susceptibility testing (MODS), may assist
to optimize the yield [75].
Due to the wide spectrum of intra- and extrathoracic disease
in children and the nonspecific nature of most signs and symp-
toms, diagnostic algorithms perform poorly. However, careful
exposure assessment, together with accurate symptom character-
ization and standard chest radiography, provides a diagnosis in
the vast majority of children [76, 77]. Tuberculosis meningitis is
the most common form of childhood meningitis seen in some
tuberculosis-endemic areas where Haemophilus influenzae type B
and conjugated pneumococcal vaccines are provided. Diagnosis
is frequently missed in resource-limited settings. A consensus
research case definition was published recently and should
be applicable irrespective of the patient’s age and HIV in-
fection status or the resources available in the diagnostics
research setting [78].
URINE-BASED DIAGNOSTIC TESTS
Urine represents a clinical sample that is easy to collect from
both adults and children and has been used extensively to
evaluate several antigen and DNA detection assays [79, 80].
Commercially available assays are able to detect lipoarabino-
mannan (LAM) in the urine of patients with tuberculosis.
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Although the sensitivity of this test has been disappointing in
non-HIV–infected patients, moderate sensitivity and high
specificity has been observed in HIV-infected patients with
advanced immunodeficiency [81]. This assay could provide
collateral evidence of tuberculosis in patients with advanced
HIV infection being screened in antiretroviral therapy clinics and
in those with possible disseminated disease. Although the sen-
sitivity of many tuberculosis diagnostic tests declines steeply in
HIV-infected patients with more advanced immunodeficiency,
paradoxically, the sensitivity of the LAM enzyme-linked im-
munosorbent assay (ELISA) increases at lower CD4 lymphocyte
cell counts [82, 83]. More than two-thirds of tuberculosis
patients with CD4 cell counts ,50 cells/lL have LAM anti-
genuria that is rapidly detectable. A cheap POC lateral flow
(Determine TB-LAM Ag urine dip-stick test) has now been
developed, which provides a qualitative (yes/no) readout of
a tuberculosis diagnosis. This assay represents a significant ad-
vance, permitting a rapid, low-cost ($3.50 per test), and specific
diagnosis of tuberculosis to be made at the point of care in
patients with very advanced HIV-associated immunodeficiency.
In a study evaluating this test as a tool for tuberculosis screening
among patients enrolling in an antiretroviral therapy clinic in
South Africa, the sensitivity was equivalent to that of the ELISA
format of the assay, and specificity was $98% overall and in all
patient subgroups stratified by CD4 cell count [84]. Although
its use appears to be limited to those with advanced HIV
infection, these are the very patients for whom the need for
rapid diagnosis is greatest.
TESTS FOR DRUG-RESISTANCE SCREENING
Drug-resistant (single drug-, multidrug-, extensively drug-, and
totally drug-resistant) tuberculosis is now well established
throughout the world [1–3, 8]. Phenotypic (culture-based)
and genotypic (nucleic acid amplification testing–based)
methods have been developed to detect drug-resistant tuber-
culosis, but first-generation tests were rarely available in tuber-
culosis-endemic areas, were poorly standardized, and had slow
turnaround times. Recent advances have changed this situation
[85–89]. Genotypic drug-susceptibility testing (DST) for first-
line agents is accurate for RIF and isoniazid (INH) but less
reliable for streptomycin, ethambutol, and pyrazinamide.
One of the most important drugs in the short-course treatment
of tuberculosis is RIF, and RIF resistance is a reliable indicator
of multidrug-resistant tuberculosis because RIF resistance in
the absence of INH resistance is rare, at least in settings using
high-quality, fixed-dose combination tablets for treatment.
Accurate genotypic DST for other first- and second-line
tuberculosis agents remains technically challenging, but
improved multiplex-PCR and improved multianalyte detection
technology should make genotypic DST a more powerful
technique in the future.
Automated liquid culture systems and molecular line probe
assays are recommended by WHO as the current gold standard
for first-line DSTs [88, 89]. Commercial automated liquid
culture DST methods are highly accurate but are expensive,
require special equipment and laboratory infrastructure, and
remain slow. The most commonly used commercially avail-
able automated liquid culture DST system is the BACTECMGIT
960 system with the BACTEC MGIT 960 SIRE kit (Becton
Dickinson, Franklin Lakes, NJ). Microscopic observation for
drug susceptibility [87] is a noncommercial test that utilizes the
markedly faster growth and microscopic cording appearance of
M. tuberculosis in liquid media to diagnoseM. tuberculosis bacilli
and provide simultaneous INH and RIF susceptibility testing.
Tests such as MODS, the nitrate reductase assay, and colori-
metric reductase methods have been conditionally approved by
WHO for use at national tuberculosis reference laboratory level
[88]. Second-line DST testing is complex and expensive and thus
not available in most high tuberculosis–endemic countries.
Liquid culture DSTs for fluoroquinolones and injectables have
relatively good reliability and reproducibility; however, DSTs
for other second-line drugs (ethionamide, prothionamide,
cycloserine, terizidone, para-aminosalicylic acid, clofazimine,
amoxicillin-clavulanate, clarithromycin, linezolid) are not
recommended. Unfortunately, tuberculosis patients in most
high tuberculosis–burden countries are rarely screened for
drug resistance due to lack of laboratory resources, high cost,
and failure to appreciate its relevance.
CHALLENGES OF DEVELOPMENT,
EVALUATION, AND IMPLEMENTATION OF
NEW TUBERCULOSIS DIAGNOSTIC TESTS
One of the main barriers to POC test development for tuber-
culosis has been the historical lack of interest, with funding
directed largely to new drug or vaccine initiatives and other
diseases such as HIV [90]. Examination of research publications
listed by the publications database search engine PubMed dur-
ing the last 5 years (2006–2011) suggests that less than 2% of the
published articles on tuberculosis diagnostic research were fo-
cused on POC tests (Figure 2). With the advent of the Xpert
MTB/RIF assay, a proliferation of publications of the evaluation
of the assay at points of care in various clinical groups and
geographical settings is anticipated. It is important that lessons
are learned from the experience of the evaluation of IGRAs over
the past decade, and properly designed and executed trials are
conducted. Further basic science breakthroughs are required to
develop novel POC technology, and the need for simpler tests
that will improve access to diagnosis and care in tuberculosis-
endemic areas requires constant emphasis and increased finan-
cial investment.
The complex nature of M. tuberculosis infection and its in-
teraction with the host remains poorly understood. Recent
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studies have found considerable variation in the antibodies ex-
pressed by tuberculosis patients, suggesting that multiple targets
will be needed if antibody-based tests are to achieve the required
sensitivity [91, 92]. The diagnostic potential of secreted antigens
and alternative biomarkers such as metabolites also need to be
explored. Once suitable markers have been identified and
validated, detection platforms must be developed that are
easy to use, safe, robust and affordable. Technological chal-
lenges include the need for minimal maintenance and oper-
ator dependence, as well as the ability to withstand highly
variable ambient temperatures, humidity, and dust. There are
also logistical difficulties to overcome relating to safety and
working with a highly infectious pathogen. Variables that
may affect the tests’ overall performance and health impact
include HIV prevalence, M. tuberculosis strain diversity, dif-
ferent environmental and genetic factors affecting particular
communities, prevalence of specific drug resistance–conferring
mutations, patient-related diagnostic delays, and health sys-
tem factors such as treatment provision and default rates.
One of the most pressing problems in tuberculosis diagnostics
is the lack of scientific rigor in manufacturer-driven validation
of new tests, compounded by the failure of regulatory bodies
to adequately assess test accuracy and appropriate implemen-
tation strategies, which allows substandard technologies to be
marketed.
OPTIMISM AND FUTURE OPPORTUNITIES
Despite many challenges, prospects for an ideal POC tubercu-
losis test are improving. With increasing recognition that better
tools are essential for early diagnosis and improved disease
control, there is mounting pressure on funding bodies to invest
in biomarker discovery and diagnostic research. Current efforts
focus on hand-held molecular devices, breath- and urine-based
assays for the detection of volatile organic compounds, micro-
chip technologies, and proteomics- and metabolomics-based
approaches for development of accurate tests, both for diagnosis
of tuberculosis disease and latent M. tuberculosis infection
[1, 24–27, 93]. It has also been acknowledged that traditional
market-led manufacturing failed to provide the tools needed to
control diseases of global importance that predominantly
affect poor people such as tuberculosis, and that future
development of tuberculosis diagnostics will benefit from
innovative public–private partnerships [11]. In 2008, the World
Health Assembly adopted a Global Strategy and Plan of Action
on Public Health, Innovation and Intellectual Property, which
has the aim of increasing product development in developing
countries.
DILEMMAS AND PRIORITIES FOR THE FUTURE
The need for cheap, accurate, rapid, sustainable POC tubercu-
losis tests has never been greater because early diagnosis is the
key to breaking the transmission cycle that sustains the tuber-
culosis epidemic [11]. There is a general consensus in the Stop
TB Partnership movement that to conquer tuberculosis we need
to detect early pulmonary disease and provide appropriate
treatment. It is also recognized that to increase access to di-
agnosis for the most vulnerable populations, improved di-
agnostic tools that can diagnose at points of care without referral
to a laboratory or skilled technical personnel are needed. There is
less agreement among experts, however, on how to make this
happen. In the past 5 years, WHO has endorsed several tech-
nologies for tuberculosis diagnosis. The majority of these have
been molecular- or culture-based technologies that require
considerable laboratory infrastructure. To implement these
technologies, a program of laboratory strengthening is being
pursued in selected tuberculosis-endemic countries. The re-
sultant centralizing of services presents a dilemma for health
planners: should they invest in a flagship laboratory with the
latest equipment or should they prioritize peripheral laborato-
ries where the majority of the population seeks care? Alterna-
tively, this may not be a question of replacing conventional
laboratory capacity but rather a question of positioning diag-
nostics at the best-suited level [94]. It must be emphasized that
all countries still need conventional culture and DST capacity.
One of the immediate priorities is rapid policy reform at the
country level to ensure optimal uptake of new diagnostics and the
Figure 2. Results of PubMed (US National Library of Medicine) was
searched using the terms ''tuberculosis'' and ''diagnosis'' and ''test'' for
articles published between 1 January 2008 and 31 December 2011. After
exclusion of inappropriate articles, duplications and reviews the articles
were reviewed and classified according to the diagnostic topic(s) or
technology(ies) they address. Point of care tests were defined as a rapid
test providing immediate results without referral to a laboratory or
specialist facility. The automated GenXpert assay is classed separately to
the manual nucleic acid amplification technologies (NAAT).
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acceptance that one size no longer fits all. Implementation of new
tools requires careful assessment at the country level of underly-
ing epidemiology, existing resources, and cost effectiveness of
different diagnostic approaches [93].
CONCLUSIONS
With limited finances, priority must be given to the de-
velopment of technologies that will reach those not being served
by current diagnostic provision. It is crucial to understand that
the development of any new, cheap, and more sensitive POC
diagnostic tests that have been proven in scientific studies and
are applicable at points of care and could facilitate progress
toward tuberculosis control will require political commitment
and resources for introduction and implementation into high-
quality, sustainable, national tuberculosis programs. Meanwhile,
more emphasis and attention is required for optimal usage of
currently available diagnostics to improve active tuberculosis
case detection rates. Simply increasing case detection rates
through existing diagnostics will go a long way in reducing
tuberculosis transmission.
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